- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 7 - Minimizing the Burden of SLE
During this segment, Michelle Petri, MD, MPH, explains how systemic lupus erythematosus (SLE) burdens patients and can lead to disability under our country’s current standard of care.
Because SLE can be a life-threatening disease, as it presents in many different ways, Dr Petri concludes that the disease’s relapsing-remitting pattern can make the disease “unpredictable.”
Dr Petri explores the importance for preventive therapy and education to help improve survival. She further explains that Europe seems to be ahead of the United States in terms of treatment adherence and claims that as many as 40% of patients with lupus aren’t taking their anti-malarial therapy regularly even though the use of hydroxychloroquine can reduce flares, lupus nephritis, thrombosis, and, in 2 different studies, has been shown to improve survival.
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Covering antiobesity medications like semaglutide could save Medicare around $500 million annually; preliminary CDC data showed a 3% decline in the number of US overdose deaths last year; the Biden administration recently announced the first national maternal mental health strategy.
Read More
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More
